The long term objective of this project is to identify the molecular defect(s) within the spectrin membrane skeleton of irreversibly sickled cells which cause these cells to lock into the sickled shape. In preliminary studies we have demonstrated that core skeletons which contain only spectrin, protein 4.1, and actin remain sickled when isolated from high density sickled cells. Furthermore, we have demonstrated that spectrin membrane skeletons. from normal red cells dissociate when prepared at 37 degrees C, while the skeletons from high density sickle cells remain associated- The fact that irreversibly sickled core skeletons remain associated at 37 degrees C is not due to covalent linkages; because these skeletons dissociate completely to spectrin, protein 4.1, and actin in the presence of SDS. Our hypothesis is that posttranslational modification(s) of spectrin, protein 4.1, or actin lead to an irreversibly sickled skeleton which resists dissociation at 37 degrees C. We will test this hypothesis with the following studies. The morphology of normal and sickle cell core skeletons prepared at 0 degrees C and 37 degrees C will he studied by negative staining and electronmicroscopy. The protein which is functionally defective will he identified by [1] studying the spectrin-4.1-f-actin interaction and spectrin dimer-dimer interaction when spectrin is isolated from control versus sickled cells. [2] Studying the spectrin-4.1-f-actin interaction when protein 4.1 is isolated from control versus sickled cells. [3] Determining the rate of polymerization of sickle cell versus control actin, and the ability of sickle cell versus normal actin protofilaments to serve as seeds for actin polymerization. Once the abnormal protein(s) have been identified the posttranslational modification(s) causing the problem will he identified by reverse phase HPLC separation of proteolytic digests of the sickle cell versus control skeletal protein, followed by protein sequencing of altered peptides by MS/MS mass spectrometry.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL038639-07
Application #
3758628
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of South Alabama
Department
Type
DUNS #
City
Mobile
State
AL
Country
United States
Zip Code
36688
Pace, B S; Qian, X; Ofori-Acquah, S F (2004) Selective inhibition of beta-globin RNA transcripts by antisense RNA molecules. Cell Mol Biol (Noisy-le-grand) 50:43-51
Haynes Jr, Johnson; Baliga, B Surendra; Obiako, Boniface et al. (2004) Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. Blood 103:3945-50
Haynes Jr, Johnson; Obiako, Boniface (2002) Activated polymorphonuclear cells increase sickle red blood cell retention in lung: role of phospholipids. Am J Physiol Heart Circ Physiol 282:H122-30
Foley, Heather A; Ofori-Acquah, Solomon F; Yoshimura, Akihiko et al. (2002) Stat3 beta inhibits gamma-globin gene expression in erythroid cells. J Biol Chem 277:16211-9
Abraham, Ann; Bencsath, F Aladar; Shartava, Archil et al. (2002) Preparation of irreversibly sickled cell beta-actin from normal red blood cell beta-actin. Biochemistry 41:292-6
Kakhniashvili, D G; Goodman, S R (2001) Isolation of spectrin subunits by reverse-phase high-performance liquid chromatography. Protein Expr Purif 23:249-51
Sangerman, J; Kakhniashvili, D; Brown, A et al. (2001) Spectrin ubiquitination and oxidative stress: potential roles in blood and neurological disorders. Cell Mol Biol Lett 6:607-36
Yang, Y M; Pace, B (2001) Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms. Pediatr Pathol Mol Med 20:87-106
Cepeda, M L; Allen, F H; Cepeda, N J et al. (2000) Physical growth, sexual maturation, body image and sickle cell disease. J Natl Med Assoc 92:4-Oct
Xu, L; Ferry, A E; Monteiro, C et al. (2000) Beta globin gene inhibition by antisense RNA transcripts. Gene Ther 7:438-44

Showing the most recent 10 out of 54 publications